Faculté des sciences et de médecine

KPC-50 confers resistance to ceftazidime-avibactam associated with reduced carbapenemase activity

Poirel, Laurent ; Vuillemin, Xavier ; Juhas, Mario ; Masseron, Amandine ; Bechtel-Grosch, Ursina ; Tiziani, Simon ; Mancini, Stefano ; Nordmann, Patrice

In: Antimicrobial Agents and Chemotherapy, 2020, vol. 64, no. 8, p. -

KPC-50 is a KPC-3 variant identified from a Klebsiella pneumoniae clinical isolate recovered in Switzerland in 2019. Compared to KPC-3, KPC-50 shows (i) a three- amino-acid insertion (Glu-Ala-Val) between amino acids 276 and 277, (ii) an increased affinity to ceftazidime, (iii) a decreased sensitivity to avibactam, explaining the ceftazidime-avibactam resistance, and (iv) an association with a... More

Add to personal list

Other files

    Summary
    KPC-50 is a KPC-3 variant identified from a Klebsiella pneumoniae clinical isolate recovered in Switzerland in 2019. Compared to KPC-3, KPC-50 shows (i) a three- amino-acid insertion (Glu-Ala-Val) between amino acids 276 and 277, (ii) an increased affinity to ceftazidime, (iii) a decreased sensitivity to avibactam, explaining the ceftazidime-avibactam resistance, and (iv) an association with a sharp reduction of its carbapenemase activity.